WO2009090962A1 - ミクロ粒子膜組成物 - Google Patents
ミクロ粒子膜組成物 Download PDFInfo
- Publication number
- WO2009090962A1 WO2009090962A1 PCT/JP2009/050393 JP2009050393W WO2009090962A1 WO 2009090962 A1 WO2009090962 A1 WO 2009090962A1 JP 2009050393 W JP2009050393 W JP 2009050393W WO 2009090962 A1 WO2009090962 A1 WO 2009090962A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microparticles
- film composition
- crosslinkable protein
- agent
- composition according
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/95—Involves in-situ formation or cross-linking of polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the present invention relates to a film composition
- a film composition comprising microparticles of a crosslinkable protein having excellent stretchability and flexibility, sufficient strength, and excellent air permeability and moisture transpiration, and a microparticle film of the crosslinkable protein It is related with the cosmetics method for correct
- Japanese Patent Laid-Open No. 11-349442 discloses wrinkles and pore combing cosmetics made of a semi-transparent spherical powder, water and silicone.
- the cosmetic composition is not cross-linked and does not have sufficient strength against strong forces such as touching with hands. It is considered that large irregularities such as cannot be corrected.
- JP 2000-16919 discloses an external preparation for correcting irregularities on the skin, including an external preparation containing a siliconized sugar compound, silicone oil, and powder.
- the external preparation composition is not cross-linked, does not have sufficient strength against a strong force such as touch with a hand, and does not have sufficient stretchability and flexibility.
- the stretchability and flexibility of the coating composition are required to follow the deformation.
- the film composition prepared from the aqueous polymer solution disclosed in the above-mentioned document does not sufficiently follow such deformation.
- the film when applied to a part that is often touched by a hand such as a face, the film needs to have sufficient strength against such physical force.
- the membrane breathability and moisture transpiration It must be excellent.
- the present invention provides a concavo-convex surface having improved stretchability and flexibility due to the cross-linking protein microparticles in the membrane composition being cross-linked by transglutaminase, and having excellent breathability and moisture transpiration.
- a film composition effective for correcting the uneven surface on the skin, a two-part skin external preparation for forming the film composition, and for correcting unevenness on the skin by using these Provide makeup method are as follows.
- a membrane composition comprising microparticles of a crosslinkable protein, wherein the microparticles of the crosslinkable protein are cross-linked with each other by transglutaminase.
- the film composition according to claim 1 wherein the microparticles of the crosslinkable protein are emulsion particles.
- the emulsion particles of the crosslinkable protein are water-in-oil emulsion particles. 4).
- the film composition according to claim 1, wherein the crosslinkable protein is gelatin, collagen or casein. 5).
- the film composition according to claim 1, wherein the microparticles of the crosslinkable protein have a particle size of 1 to 30 ⁇ m. 6).
- the film composition according to claim 1, wherein the ratio of the crosslinkable protein component in the film composition is 1% by mass to 20% by mass. 7).
- the film composition according to claim 1, wherein a ratio of the crosslinkable protein component in the film composition is 5% by mass to 15% by mass. 8).
- the film composition according to claim 1, wherein a ratio of the crosslinkable protein component in the film composition is 8% by mass to 12% by mass.
- the membrane composition according to claim 1, wherein the amount of transglutaminase for cross-linking the cross-linkable protein microparticles to each other is 1 U to 20 U per gram of cross-linkable protein component. 10.
- the membrane composition according to claim 1, wherein the amount of transglutaminase for cross-linking the microparticles of the crosslinkable protein to each other is 1.5 U to 10 U per 1 g of the crosslinkable protein component. 11. The membrane composition according to claim 1, wherein the amount of transglutaminase for cross-linking the microparticles of the cross-linkable protein to each other is 5 U to 10 U per 1 g of the cross-linkable protein component. 12
- the film composition according to claim 1, wherein the crosslinkable protein microparticles further comprise an anionic polymer component. 14 The film composition according to claim 1, wherein the anionic polymer is polyglutamic acid. 15.
- the film composition according to claim 1, wherein the ratio of the anionic polymer component in the film composition is 0.01% by mass to 0.5% by mass.
- the microparticles of the crosslinkable protein further comprise a polyhydric alcohol component.
- the polyhydric alcohol component is glycerin.
- the ratio of the polyhydric alcohol component in the film composition is 1% by mass to 50% by mass. 19.
- a two-part skin external preparation for forming a film on the skin surface by cross-linking crosslinkable protein microparticles with each other, comprising a first agent containing crosslinkable protein microparticles, and transglutaminase A two-part skin external preparation comprising: 20. The two-part skin external preparation, wherein the microparticles of the crosslinkable protein contained in the first agent are emulsion particles. 21. The two-part skin external preparation, wherein the emulsion particles of the crosslinkable protein contained in the first agent are water-in-oil emulsion particles. 22. The two-part skin external preparation, wherein the microparticles in the first agent further comprise an anionic polymer component. 23.
- the two-part skin external preparation wherein the anionic polymer is polyglutamic acid.
- the two-part skin external preparation wherein the microparticles in the first agent further comprise a polyhydric alcohol component.
- the two-part skin external preparation, wherein the polyhydric alcohol component is glycerin. 26.
- a cosmetic method for correcting unevenness on the skin surface wherein a mixture of a first agent containing microparticles of a crosslinkable protein and a second agent containing transglutaminase is applied to a desired site on the skin surface.
- a cosmetic process comprising forming a film in which the microparticles of the crosslinkable protein are crosslinked to each other.
- the microparticles of the crosslinkable protein contained in the first agent are emulsion particles.
- the emulsion particles of the crosslinkable protein contained in the first agent are water-in-oil emulsion particles.
- the microparticles in the first agent further comprise an anionic polymer component.
- the anionic polymer is polyglutamic acid.
- the microparticles in the first agent further comprise a polyhydric alcohol component.
- the polyhydric alcohol component is glycerin.
- FIG. 2 is a photograph showing the stretchability and flexibility of a gelatin particle film prepared by a water-in-oil emulsion method.
- 6 is a graph showing time-dependent changes in the adsorption and release of methylene blue in microparticle assembly A and bulk gel A, microparticle assembly C and bulk gel C.
- 3 is a graph showing stress-strain curves in microparticle assemblies A, B and C. It is a graph which shows the water
- ESEM environmental control electron microscope
- crosslinkable protein means a gelable protein having a high crosslinking ability, and a protein that can be crosslinked by transglutaminase is particularly preferred.
- crosslinkable proteins include gelatin, collagen, and casein, for example.
- microparticle is intended to include both crosslinked and non-crosslinked particles of the crosslinkable protein.
- crosslinked particles mean particles gelled in a solvent by crosslinking
- non-crosslinked particles mean emulsion particles not gelled in a solvent by crosslinking.
- a film composition comprising microparticles of crosslinkable protein.
- the microparticles of the crosslinkable protein are preferably emulsion particles.
- the emulsion particles of the crosslinkable protein are preferably water-in-oil emulsion particles.
- the water-in-oil emulsion particles have a micelle structure in which the continuous phase (outer phase) is an oil component and the dispersed phase (inner phase) is an aqueous solution of a crosslinkable protein.
- the water-in-oil emulsion particles of the crosslinkable protein are prepared by adding an aqueous solution of a crosslinkable protein such as gelatin, collagen or casein to the dispersion (oil), and mechanical means such as ultrasound, propeller stirring group , A paddle mixer, a homomixer, and a colloid mill, and by adding a surfactant as necessary.
- a crosslinkable protein such as gelatin, collagen or casein
- mechanical means such as ultrasound, propeller stirring group , A paddle mixer, a homomixer, and a colloid mill
- the oil used to form the emulsion in the present invention may be any oil conventionally used in the art to form a water-in-oil emulsion as long as it is not harmful to the human body.
- the particle size of the crosslinkable protein microparticles for example, the emulsion particles is 0.1 ⁇ m to 100 ⁇ m, preferably 0.1 ⁇ m to 80 ⁇ m, more preferably 1 ⁇ m to 30 ⁇ m.
- the particle size of the microparticles should be measured by means conventionally used in the industry, for example, laser light scattering method, Coulter counter method, etc., using, for example, PAR-IIIs (PHOTON CORRELATER) (Otsuka Electronics Co., Ltd.) Can do.
- Transglutaminase is added to the cross-linkable protein microparticles, for example, emulsion particles, and, for example, at room temperature to 45 ° C, preferably 30 ° C to 40 ° C, and most preferably body temperature, for example, 5 minutes.
- the microparticles undergo cross-linking polymerization, thereby forming a film comprising microparticles of cross-linkable protein.
- the gel film containing microparticles obtained in this manner has many gaps between fine particles of protein, and is considered to have excellent air permeability and moisture transpiration as compared with bulk gel.
- cross-linking between particles makes it possible to obtain sufficient stretchability, flexibility and strength for application to the skin.
- Transglutaminase is a family of acyltransferases that depend on calcium and thiol, which are widely present in nature. It catalyzes the formation of amide bonds between the ⁇ -carboxamide group of peptide-bound glutamine residues and the primary amino group of various compounds, such as the ⁇ -amino group of lysine present in specific proteins. It is an enzyme that is widely used for post-translational modification of proteins by incorporation and cross-linking of proteins.
- the transglutaminase used in the present invention is not particularly limited in its origin, and may be, for example, a microorganism-derived transglutaminase, a mammal-derived transglutaminase, a fish-derived transglutaminase, or a derivative thereof.
- These transglutaminases are commercially available, and can be purchased, for example, from Ajinomoto Co., Inc. under the trade name Activa.
- the ratio of the crosslinkable protein component in the film composition of the present invention affects the hardness of the film composition, that is, stretchability, flexibility, strength, and the like.
- the proportion of the crosslinkable protein component in the membrane composition suitable for skin application is 1% to 20% by weight, preferably 5% to 15% by weight, more preferably 8% to 12% by weight. is there.
- the amount of transglutaminase added in the cross-linking of the cross-linkable protein microparticles affects the degree of cross-linking of the protein component.
- the amount of transglutaminase to form a suitable crosslink is 1U-20U per gram of crosslinkable protein component, preferably 1.5U-10U per gram of crosslinkable protein component, more preferably 1g of crosslinkable protein. 5 U to 10 U per ingredient.
- U (unit) used as a unit of enzyme amount represents the amount of enzyme activity, and 1 U represents 1 ⁇ mol of substrate (in the present invention, a crosslinkable protein, for example, , Gelatin, collagen or casein).
- the microparticle is mainly composed of a crosslinkable protein.
- an anionic polymer is added together with the crosslinkable protein component in an aqueous swelling solvent (for example, an aqueous sodium chloride solution).
- a portion of the cross-linkable protein polymer composition of the microparticles can be replaced with the anionic polymer. Since the anionic polymer has a carboxyl group or the like in its side chain, it is possible to further improve the properties of the microparticle film composition of the present invention by imparting the characteristics of the functional group.
- the improved properties include an increase in the amount of substances having an opposite potential of an anionic polymer (for example, a cationic dye), suppression of release of the gel-encapsulating substance due to a concentration gradient, an increase in the flexibility of the membrane composition, and bending Examples include enhancement of crack resistance, improvement of followability to tension, and improvement of gel swelling due to repulsion of an ionic group derived from an anionic polymer.
- an anionic polymer for example, a cationic dye
- anionic polymer (the molecular weight of the polymer is 10,000 to 10,000,000, preferably 100,000 to 5,000,000, optimally 500,000 to 1,000,000 when measured by a static light scattering method) is harmful to the human body.
- anionic polyamino acids such as polyglutamic acid and polyaspartic acid, agar, hyaluronic acid, chondroitin sulfate, succinoglucan, gum arabic, xanthan gum, carboxymethylcellulose and the like are preferable. Examples thereof include polysaccharides and polyacrylic acid, and polyglutamic acid is particularly preferable.
- the proportion of the anionic polymer component in the membrane composition is 0.01% to 0.5% by weight, preferably 0.1% to 0.5% by weight, more preferably about 0.2% by weight. % To 0.4% by mass.
- a polyhydric alcohol is added to the crosslinkable protein microparticle aqueous swelling solvent (for example, sodium chloride aqueous solution), thereby forming a crosslinkable protein microparticle swelling solvent.
- aqueous swelling solvent for example, sodium chloride aqueous solution
- a polyhydric alcohol component can be contained.
- polyhydric alcohol since polyhydric alcohol has a high affinity with water, even when the evaporation of the swelling solvent of the microparticle reaches equilibrium, it can remain in the microparticle without being evaporated. In this way, by containing a polyhydric alcohol component in the microparticles of the crosslinkable protein, it is possible to suppress the moisture transpiration of the film composition and improve the water retention of the film composition of the present invention. is there.
- the polyhydric alcohol is not limited and may be any conventionally used as a humectant in the art, such as glycerin, xylitol, diglycerin, dipropylene glycol, sorbitol, DL-pyrrolidone.
- examples include sodium carboxylate, propylene glycol, butylene glycol, polyethylene glycol, polyglycerin, polyoxyethylene methyl glucoside, maltitol, mannitol, and polyvinyl alcohol.
- Glycerin is preferred.
- the ratio of the polyhydric alcohol component in the film composition is 1 to 50% by mass, preferably 3 to 30% by mass, and more preferably about 5 to 15% by mass.
- the film composition thus obtained has uneven surfaces, for example, unevenness on the skin, for example, keloid marks due to burns, skin grafts, surgical marks, deep wrinkles, deep scars, acne marks, large pores, fine lines, etc. It can be applied to correct.
- uneven surfaces for example, unevenness on the skin, for example, keloid marks due to burns, skin grafts, surgical marks, deep wrinkles, deep scars, acne marks, large pores, fine lines, etc. It can be applied to correct.
- the film composition of the present invention is capable of following the movement of the skin, and since air permeability and moisture transpiration are ensured through the gap formed between the particles, the skin condition can be kept healthy. Is possible. Therefore, the film composition of the present invention can be provided as a film for correcting the uneven surface on the skin, for example, and can be provided as a disposable form.
- the terms “membrane composition” and “assembly” are used synonymously. Regardless of the thickness, size, etc., the microparticles of the crosslinkable protein are aggregated by transglutaminase. Means the body.
- a two-part skin external preparation for forming a film on the skin surface by cross-linking the crosslinkable protein microparticles, preferably emulsion particles.
- the two-part skin external preparation comprises a first agent containing crosslinkable protein microparticles, preferably emulsion particles, and a second agent containing transglutaminase.
- the crosslinkable protein component is blended in a proportion of about 1 to 20% by mass, preferably 3 to 10% by mass, more preferably 3 to 5% by mass.
- the microparticles in the first agent may further contain an anionic polymer component and / or a polyhydric alcohol component. These preferred specific examples and concentrations are as described above.
- the amount of transglutaminase is about 1 to 20 U, preferably 2.5 U to 10 U, more preferably 5 U to 10 U per gram of crosslinkable protein component. Blended.
- Both the first agent and / or the second agent can be formulated into a dosage form that can be easily applied to the skin.
- a dosage form that can be easily applied to the skin.
- lotion preparations, emulsions, creams, ointments, plasters, etc. can be prescribed.
- microparticles of crosslinkable protein for example, emulsion particles can be dissolved in a solvent.
- a solvent for the first agent for example, chain polysiloxane, cyclic polysiloxane, modified polysiloxane, squalane, isopropyl myristate, cetyl octanoate, isopropyl palmitate, glycerin trioctanoate, tetra-2-ethylhexanoic acid Examples include pentaerythritol, diisobutyl adipate, di-2-ethylhexyl sebacate, olive oil, jojoba oil, and germ oil.
- the second agent can also be formulated by dissolving a transglutaminase crystal in a solvent.
- a solvent for the second agent for example, sterilized water, a buffer solution, or the like can be used.
- excipients In the preparation of the first agent and / or the second agent, excipients, fragrances, oils and fats, surfactants, preservatives conventionally used in the art as long as the efficacy of the present invention is not impaired.
- excipients optionally contain a sequestering agent, water-soluble polymer, thickener, powder component, UV protection agent, moisturizer, medicinal component, antioxidant, pH adjuster, cleaning agent, desiccant, emulsifier, etc.
- a sequestering agent water-soluble polymer, thickener, powder component, UV protection agent, moisturizer, medicinal component, antioxidant, pH adjuster, cleaning agent, desiccant, emulsifier, etc.
- the two-part skin external preparation is preferably provided as a kit containing the first and second agents. It is preferable that the kit includes instructions clearly showing the handling of the first agent and the second agent.
- a cosmetic method for correcting irregularities on the skin surface is provided.
- a first agent containing crosslinkable protein microparticles, preferably emulsion particles, and a second agent containing transglutaminase are mixed, and the mixture is mixed with a desired site on the skin, for example, the skin,
- the skin For example, it is applied to unevenness on the face, keloid marks due to burns, skin graft marks, surgical marks, deep wrinkles, deep scars, acne marks, large pores, fine wrinkles, etc., or the first agent and the second agent are applied as described above Apply separately to the site and mix on the application site, and mix the mixture of the first and second agents under optimal conditions, eg, room temperature to 45 ° C., preferably 30 ° C.
- Preparation method of gelatin particles by W / O emulsion method Preparation of non-crosslinked gelatin particles 9 ml of 5% gelatin (GSB, Nippi Co., Ltd.) (gelatin from cowhide and cow bones, jelly strength: 260-290 g, viscosity: 3.0- (4.0 mPa) aqueous solution was added to 21 ml of decamethylcyclopentasiloxane and ultrasonically dispersed to obtain a W / O type emulsion. The settled particles were collected with a pipette to obtain non-crosslinked gelatin particles.
- the film composition exhibits these properties in both the stretched and folded polyurethanes to which the emulsion particle film of the crosslinkable protein of the present invention is applied.
- the microparticle film of the present invention has high stretchability and flexibility and can sufficiently follow the deformation of the skin.
- microparticle assembly A Preparation of microparticle assembly A and bulk gel A (10% by weight gelatin) 10 U transglutaminase per gram of gelatin was added to non-crosslinked emulsion particles of 10% by weight of gelatin prepared by the same W / O emulsion method as in Example 1 to crosslink the inside of the emulsion particles, and into 10 mM sodium chloride aqueous solution.
- Cross-linked gelatin particles (microparticles A) that were dispersed to reach a swelling equilibrium were obtained.
- the crosslinked gelatin particles were collected, and transglutaminase was further added to crosslink the particles to obtain a microparticle assembly (microparticle assembly A).
- a bulk gel containing 10% by mass of gelatin was prepared by a conventional method, and immersed in a 10 mM sodium chloride aqueous solution to reach a swelling equilibrium (bulk gel A).
- microparticle assembly B and bulk gel B by adding glycerin to swelling solvent (10 wt% gelatin + 10 wt% glycerin) 10 U of transglutaminase per gram of gelatin was added to non-crosslinked emulsion particles of 10% by weight gelatin prepared by the same W / O emulsion method as in Example 1 to crosslink the emulsion particles, and 10% by weight of glycerin ( Cross-linked gelatin particles (microparticles B) which have been dispersed in a 10 mM sodium chloride aqueous solution containing Wako Pure Chemical Industries, Ltd. and have reached a swelling equilibrium were obtained.
- swelling solvent 10 wt% gelatin + 10 wt% glycerin
- microparticle assembly B The crosslinked gelatin particles were collected, and transglutaminase was further added to crosslink the particles to obtain a microparticle assembly (microparticle assembly B).
- a bulk gel containing 10% by weight of gelatin was immersed in a 10 mM sodium chloride aqueous solution containing 10% by weight of glycerin to reach a swelling equilibrium (bulk gel B).
- microparticle assembly C This was dispersed in a 10 mM aqueous sodium chloride solution to obtain crosslinked gelatin particles (microparticles C) that reached a swelling equilibrium.
- the crosslinked gelatin particles were collected, and transglutaminase was further added to crosslink the particles to obtain a microparticle assembly (microparticle assembly C).
- a bulk gel composed of 9.7% by mass of gelatin and 0.3% by mass of PGA was prepared by a conventional method, and immersed in a 10 mM sodium chloride aqueous solution to reach a swelling equilibrium (bulk gel C).
- Adsorption / release behavior of dye A solution containing 56 ⁇ M of gel (18 ⁇ 18 ⁇ 2 mm) in a swelling equilibrium at pH 6 and cationic methylene blue di-trihydrate (MB) (Pure Chemical Co., Ltd.) at a predetermined concentration It was immersed in (ionic strength 0.01, 15 mL for each measurement), and this time was 0 hour. Absorbance was measured while stirring gently with a stirrer over time (620 nm, MPR A4i microplate reader manufactured by Tosoh Corporation), and the amount of MB contained in the gel was calculated by subtracting the external solution concentration from the charged concentration. Next, the gel adsorbing MB was immersed in a pH 2 solution containing no MB, and the absorbance was measured in the same manner to calculate the amount of MB contained in the gel.
- MB cationic methylene blue di-trihydrate
- the microparticle assembly A showed a quicker response than the bulk gel A.
- the amount of MB adsorbed in gels (microparticle assembly C, bulk gel C) in which PGA was introduced into gelatin increased as compared to gelatin-only gels (microparticle assembly A, bulk gel A).
- the gel (microparticle assembly C, bulk gel C) in which PGA is introduced into gelatin and the gel containing only gelatin (microparticle assembly A, bulk gel A) have almost no difference in amino group content, the pH is adjusted to 6 In the system changed to 2, there was no significant difference in the release behavior, but in the system released at the same pH 6 as the adsorption conditions, MB release due to the concentration gradient was suppressed.
- the concentration gradient is the main driving force for dye release even under the condition that electrostatic attraction works with MB, but by introducing PGA into the gel, It is considered that dye release due to the concentration gradient is suppressed because the action of retaining the MB adsorbed by the electrostatic attractive force inside the gel is enhanced.
- Example 2 Gel Bending / Tensing followability
- Each microparticle assembly prepared in Example 2 was prepared in the same manner on a polyurethane sponge, and the shape of the polyurethane sponge was deformed to change the bending / pulling of each microparticle assembly attached to the sponge.
- the followability in tension was examined.
- the microparticle assembly in which PGA was introduced into gelatin (microparticle assembly C) showed excellent bending / pulling followability as compared with the microparticle assembly containing only gelatin (microparticle assembly A).
- Moisture transpiration of the gel By measuring over time the weight of 10 ⁇ l of the 1.2% by weight dispersion of each microparticle prepared in Example 2 and the control (sodium chloride aqueous solution and sodium chloride + glycerin aqueous solution) (temperature 22 ° C. In a constant temperature and humidity chamber with a relative humidity of 45%, the water transpiration of each solution was evaluated. As a result, the microparticles (microparticle B) dispersed in a 10 mM sodium chloride aqueous solution containing 10% by mass of glycerin and reaching the swelling equilibrium significantly suppressed moisture transpiration as compared with other microparticles. (FIG. 4).
- the line roughness is a value indicating, in micrometer units, how much the unevenness in the height direction of the sample surface is on average from the central reference line.
- Line roughness means arithmetic average roughness (Ra), and was calculated according to the definition of JIS B 0601-1994. The measured value is shown as an average value of 10-point measurement.
- Example 2 Evaluation of shrinkage due to drying
- Each gel prepared in Example 2 of 18 ⁇ 18 ⁇ 1 mm was placed on a medicine-wrapped paper and dried overnight at a relative humidity of 43%.
- the shrinkage of the gel due to drying was evaluated by the deformation of the medicine wrapping paper drawn into the drying of the gel.
- the microparticle assembly had significantly less shrinkage due to drying than the bulk gel (FIG. 6). This is because the constituent polymers of the bulk gel are intertwined together, but the microparticle assembly is an aggregate of particles in the order of micrometers, so the effect of drying shrinkage of one microparticle on the surrounding microparticles This is considered to be because the deformation as a whole is small.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
2.前記架橋性タンパク質のミクロ粒子がエマルション粒子であることを特徴とする、前記膜組成物。
3.前記架橋性タンパク質のエマルション粒子が油中水型エマルション粒子であることを特徴とする、前記膜組成物。
4.前記架橋性タンパク質が、ゼラチン、コラーゲン又はカゼインであることを特徴とする、前記膜組成物。
5.前記架橋性タンパク質のミクロ粒子の粒径が、1~30μmであることを特徴とする、前記膜組成物。
6.前記膜組成物中の架橋性タンパク質成分の割合が、1質量%~20質量%であることを特徴とする、前記膜組成物。
7.前記膜組成物中の架橋性タンパク質成分の割合が、5質量%~15質量%であることを特徴とする、前記膜組成物。
8.前記膜組成物中の架橋性タンパク質成分の割合が、8質量%~12質量%であることを特徴とする、前記膜組成物。
9.前記架橋性タンパク質のミクロ粒子を互いに架橋するためのトランスグルタミナーゼの量が、1gの架橋性タンパク質成分あたり1U~20Uであることを特徴とする、前記膜組成物。
10.前記架橋性タンパク質のミクロ粒子を互いに架橋するためのトランスグルタミナーゼの量が、1gの架橋性タンパク質成分あたり1.5U~10Uであることを特徴とする、前記膜組成物。
11.前記架橋性タンパク質のミクロ粒子を互いに架橋するためのトランスグルタミナーゼの量が、1gの架橋性タンパク質成分あたり5U~10Uであることを特徴とする、前記膜組成物。
12.凹凸表面を補正するために使用される、前記膜組成物。
13.前記架橋性タンパク質のミクロ粒子がアニオン性ポリマー成分をさらに含んで成ることを特徴とする、前記膜組成物。
14.前記アニオン性ポリマーがポリグルタミン酸であることを特徴とする、前記膜組成物。
15.前記膜組成物中のアニオン性ポリマー成分の割合が、0.01質量%~0.5質量%であることを特徴とする、前記膜組成物。
16.前記架橋性タンパク質のミクロ粒子が多価アルコール成分をさらに含んで成ることを特徴とする、前記膜組成物。
17.前記多価アルコール成分がグリセリンであることを特徴とする、前記膜組成物。
18.前記膜組成物中の多価アルコール成分の割合が、1質量%~50質量%であることを特徴とする、前記膜組成物。
19.架橋性タンパク質のミクロ粒子を互いに架橋することにより皮膚表面上に膜を形成するための2剤式皮膚外用剤であって、架橋性タンパク質のミクロ粒子を含有する第1剤、及びトランスグルタミナーゼを含有する第2剤、を含んで成る2剤式皮膚外用剤。
20.前記第1剤に含有される架橋性タンパク質のミクロ粒子がエマルション粒子であることを特徴とする、前記2剤式皮膚外用剤。
21.前記第1剤に含有される架橋性タンパク質のエマルション粒子が油中水型エマルション粒子であることを特徴とする、前記2剤式皮膚外用剤。
22.前記第1剤中のミクロ粒子がアニオン性ポリマー成分をさらに含んで成ることを特徴とする、前記2剤式皮膚外用剤。
23.前記アニオン性ポリマーがポリグルタミン酸であることを特徴とする、前記2剤式皮膚外用剤。
24.前記第1剤中のミクロ粒子が多価アルコール成分をさらに含んで成ることを特徴とする、前記2剤式皮膚外用剤。
25.前記多価アルコール成分がグリセリンであることを特徴とする、前記2剤式皮膚外用剤。
26.皮膚表面の凹凸を補正するための化粧方法であって、架橋性タンパク質のミクロ粒子を含有する第1剤及びトランスグルタミナーゼを含有する第2剤の混合物を皮膚表面上の所望の部位に適用するか、あるいは該第1剤及び第2剤を別々に皮膚表面上の所望の部位に適用することにより混合し、そして該部位上で第1剤及び第2剤の混合物を乾燥させることにより、皮膚表面上に該架橋性タンパク質のミクロ粒子が互いに架橋した膜を形成させることを含んで成る、化粧方法。
27.前記第1剤に含有される架橋性タンパク質のミクロ粒子がエマルション粒子であることを特徴とする、前記化粧方法。
28.前記第1剤に含有される架橋性タンパク質のエマルション粒子が油中水型エマルション粒子であることを特徴とする、前記化粧方法。
29.前記第1剤中のミクロ粒子がアニオン性ポリマー成分をさらに含んで成ることを特徴とする、前記化粧方法。
30.前記アニオン性ポリマーがポリグルタミン酸であることを特徴とする、前記化粧方法。
31.前記第1剤中のミクロ粒子が多価アルコール成分をさらに含んで成ることを特徴とする、前記化粧方法。
32.前記多価アルコール成分がグリセリンであることを特徴とする、前記化粧方法。
非架橋ゼラチン粒子の調製
9mlの5%ゼラチン(GSB,株式会社ニッピ)(牛皮・牛骨由来ゼラチン,ゼリー強度:260~290g,粘度:3.0~4.0mPa)水溶液を21mlのデカメチルシクロペンタシロキサンに加え、超音波分散してW/O型エマルションを得た。沈降した粒子をピペットで回収し、非架橋ゼラチン粒子を得た。
1mlの上記非架橋ゼラチン粒子に3Uのトランスグルタミナーゼ(味の素株式会社)(分子量:3万8千)を添加して混合した後、皮膚の代替物としてポリウレタンスポンジ上に直径約2cm、厚さ約3mmの大きさの穴を開け、ここに該混合物を滴下し、そして展開した。その後相対湿度65%、40℃において1時間反応させ、ゲル粒子膜を得た。
図1に示されるとおり、本発明の架橋性タンパク質のエマルション粒子膜を適用したポリウレタンを引き伸ばした場合、及び折り曲げた場合の両方において、該膜組成物はこれらの動きに追従した。従って本発明のミクロ粒子膜は、高い伸縮性及び柔軟性を有し、皮膚の変形に対しても十分に追従可能であることが確認された。
実施例1と同様のW/Oエマルション法により調製したゼラチン10質量%の非架橋エマルション粒子に、ゼラチン1gあたり10Uのトランスグルタミナーゼを添加してエマルション粒子内部を架橋し、10mMの塩化ナトリウム水溶液中に分散して膨潤平衡に到達させた架橋ゼラチン粒子(ミクロ粒子A)を得た。該架橋ゼラチン粒子を回収し、さらにトランスグルタミナーゼを添加して粒子間を架橋させてミクロ粒子アセンブリー(ミクロ粒子アセンブリーA)を得た。一方、定法によりゼラチン10質量%のバルクゲルを調製し、10mMの塩化ナトリウム水溶液中に浸漬して膨潤平衡に到達させた(バルクゲルA)。
実施例1と同様のW/Oエマルション法により調製したゼラチン10質量%の非架橋エマルション粒子に、ゼラチン1gあたり10Uのトランスグルタミナーゼを添加してエマルション粒子内部を架橋し、そして10質量%のグリセリン(和光純薬工業社)を含有した10mMの塩化ナトリウム水溶液中に分散して膨潤平衡に到達した架橋ゼラチン粒子(ミクロ粒子B)を得た。該架橋ゼラチン粒子を回収し、さらにトランスグルタミナーゼを添加して粒子間を架橋させてミクロ粒子アセンブリー(ミクロ粒子アセンブリーB)を得た。一方、定法によりゼラチン10質量%のバルクゲルを10質量%のグリセリンを含有した10mMの塩化ナトリウム水溶液中に浸漬して膨潤平衡に到達させた(バルクゲルB)。
実施例1と同様のW/Oエマルション法において、ゼラチン溶液にポリグルタミン酸(分子量:約800,000)をさらに添加することにより、ゼラチン9.7質量%とポリグルタミン酸0.3質量%から構成される非架橋エマルション粒子を調製し、そしてゼラチン1gあたり10Uのトランスグルタミナーゼを添加してエマルション粒子内部を架橋させた。これを10mMの塩化ナトリウム水溶液中に分散して膨潤平衡に到達させた架橋ゼラチン粒子(ミクロ粒子C)を得た。該架橋ゼラチン粒子を回収し、さらにトランスグルタミナーゼを添加して粒子間を架橋させてミクロ粒子アセンブリー(ミクロ粒子アセンブリーC)を得た。一方、定法によりゼラチン9.7質量%とPGA0.3質量%から構成されるバルクゲルを調製し、10mMの塩化ナトリウム水溶液中に浸漬して膨潤平衡に到達させた(バルクゲルC)。
pH6において膨潤平衡状態にあるゲル(18×18×2mm)を、所定濃度でカチオン性のメチレンブルー二~三水和物(MB)(純正化学工業社)を56μM含有する溶液(イオン強度0.01,各測定につき15mL)に浸漬し、この時点を0時間とした。経時で緩やかにスターラーで撹拌しながら吸光度測定を行い(620nm,東ソー(株)製 MPR A4iマイクロプレートリーダー)、ゲル内部に内包されるMB量は仕込み濃度から外液濃度を差し引いて算出した。次に、MBを吸着したゲルを、MBを含まないpH2の溶液に浸漬し、同様にして吸光度測定を行い、ゲル内部に内包されるMB量を算出した。
実施例2において調製した各ゲルに対してFUDOHレオメーターNRM-2010J-CW((株)レオテック製)を用いて応力-歪測定を行った。測定条件は、プランジャー直径:3.015mm(バルクゲル測定)、10.05mm(ミクロゲルアセンブリー測定)、試料サイズ:直径18mm×高さ10mmの円柱形、膨潤状態のゲルとし、プランジャーを試料に侵入させて破断強度を測定した。歪は(プランジャー侵入長/試料の初期厚さ)×100(%)として計算した。その結果、ゼラチンに対してPGAを導入したゲル(ミクロ粒子アセンブリーC、バルクゲルC)は、他のゲルに比較して強度が減少ししなやかさが増加した(図3)。これは高いイオン性をもつPGA分子鎖がゼラチン鎖と絡み合い、ゼラチン鎖同士の分子間相互作用を低めているためと考えられる。高いイオン性をもつPGA分子鎖の静電斥力によって酵素反応が阻害され、粒子間の架橋がミクロゲルアセンブリーAよりも希薄となったためであり、また、しなやかさの増加はミクロゲルの膨潤度が高いためと考えられる。
ポリウレタンスポンジ上で実施例2にて調製された各ミクロ粒子アセンブリーを同様に調製し、ポリウレタンスポンジの形状を変形させることによって、スポンジに付着した各ミクロ粒子アセンブリーの曲げ・引っ張りにおける追随性を検討した。その結果、ゼラチンにPGAを導入したミクロ粒子アセンブリー(ミクロ粒子アセンブリーC)は、ゼラチンのみを含むミクロ粒子アセンブリー(ミクロ粒子アセンブリーA)と比較して、優れた曲げ・引っ張り追随性を示した。
対照(塩化ナトリウム水溶液及び塩化ナトリウム+グリセリン水溶液)と実施例2において調製した各ミクロ粒子の1.2質量%分散液10μlの重量を経時的に測定することにより(温度22℃、相対湿度45%の恒温恒湿室中)、各溶液の水分蒸散性を評価した。その結果、10質量%のグリセリンを含有した10mMの塩化ナトリウム水溶液中に分散して膨潤平衡に到達したミクロ粒子(ミクロ粒子B)は、他のミクロ粒子に比較して水分蒸散を顕著に抑制した(図4)。
実施例2において調製した各ゲルの乾燥前後の表面形状を環境制御型電子顕微鏡(ESEM)FEI Quanta 200((株)ニコンインステック製、撮影倍率:×1,000)により評価した。ゼラチンのみおよびPGA含有ミクロ粒子アセンブリーは乾燥後には完全に球形の形が潰れ、粒子間空隙が無くなってしまうが、グリセリン含有アセンブリーでは乾燥後もくっきりと粒子の形状が維持されていることがわかる(図5)。また、超深度形状測定顕微鏡((株)KEYENCE製 超深度形状測定顕微鏡 VK-8500)を用いて線粗さを測定することによって、ゲル粒子の膨潤率を数値的に評価することができる。線粗さとは、試料表面の高さ方向の凹凸が中央の基準線から平均してどれだけ幅があるかをマイクロメートル単位で示した値である。測定方法としては、スライドガラスに挟んで作製したアセンブリーを膨潤状態のまま、あるいは室内で一晩乾燥させた後に測定した。線粗さは算術平均粗さ(Ra)を意味しており、JIS B 0601-1994の定義に従い算出した。測定値は10点測定の平均値として示してある。乾燥後の各ミクロ粒子アセンブリーの線粗さを比較した場合、グリセリ含有ミクロ粒子アセンブリーの数値が高いことからも、膨潤溶媒中のグリセリンの添加によってゲルの保湿性が改善され、乾燥によるミクロ粒子アセンブリーの表面形状の変化が抑制されることがわかる。
18×18×1mmの実施例2において調製した各ゲルを薬包紙上に置き、相対湿度43%で一晩乾燥させた。ゲルの乾燥に引き込まれた薬包紙の変形により乾燥に伴うゲルの縮み評価を行った。その結果、ミクロ粒子アセンブリーはバルクゲルに比較して乾燥に伴う縮みが顕著に少なかった(図6)。これは、バルクゲルの構成ポリマーが一体となって絡まりあっているのに対し、ミクロ粒子アセンブリーはマイクロメートル・オーダーの粒子の集合体であるためミクロ粒子1つの乾燥収縮が周囲のミクロ粒子に与える影響が小さく、全体としての変形が小さくなるためと考えられる。
Claims (32)
- 架橋性タンパク質のミクロ粒子を含んで成る膜組成物であって、該架橋性タンパク質のミクロ粒子が、互いに、トランスグルタミナーゼにより架橋されていることを特徴とする、膜組成物。
- 前記架橋性タンパク質のミクロ粒子がエマルション粒子であることを特徴とする、請求項1に記載の膜組成物。
- 前記架橋性タンパク質のエマルション粒子が油中水型エマルション粒子であることを特徴とする、請求項2に記載の膜組成物。
- 前記架橋性タンパク質が、ゼラチン、コラーゲン又はカゼインであることを特徴とする、請求項1~3のいずれか一項に記載の膜組成物。
- 前記架橋性タンパク質のミクロ粒子の粒径が、1~30μmであることを特徴とする、請求項1~4のいずれか一項に記載の膜組成物。
- 前記膜組成物中の架橋性タンパク質成分の割合が、1質量%~20質量%であることを特徴とする、請求項1~5のいずれか一項に記載の膜組成物。
- 前記膜組成物中の架橋性タンパク質成分の割合が、5質量%~15質量%であることを特徴とする、請求項6に記載の膜組成物。
- 前記膜組成物中の架橋性タンパク質成分の割合が、8質量%~12質量%であることを特徴とする、請求項7に記載の膜組成物。
- 前記架橋性タンパク質のミクロ粒子を互いに架橋するためのトランスグルタミナーゼの量が、1gの架橋性タンパク質成分あたり1U~20Uであることを特徴とする、請求項1~8のいずれか一項に記載の膜組成物。
- 前記架橋性タンパク質のミクロ粒子を互いに架橋するためのトランスグルタミナーゼの量が、1gの架橋性タンパク質成分あたり1.5U~10Uであることを特徴とする、請求項9に記載の膜組成物。
- 前記架橋性タンパク質のミクロ粒子を互いに架橋するためのトランスグルタミナーゼの量が、1gの架橋性タンパク質成分あたり5U~10Uであることを特徴とする、請求項10に記載の膜組成物。
- 凹凸表面を補正するために使用される、請求項1~11のいずれか一項に記載の膜組成物。
- 前記架橋性タンパク質のミクロ粒子がアニオン性ポリマー成分をさらに含んで成ることを特徴とする、請求項1~12のいずれか一項に記載の膜組成物。
- 前記アニオン性ポリマーがポリグルタミン酸であることを特徴とする、請求項13に記載の膜組成物。
- 前記膜組成物中のアニオン性ポリマー成分の割合が、0.01質量%~0.5質量%であることを特徴とする、請求項13または14に記載の膜組成物。
- 前記架橋性タンパク質のミクロ粒子が多価アルコール成分をさらに含んで成ることを特徴とする、請求項1~15のいずれか一項に記載の膜組成物。
- 前記多価アルコール成分がグリセリンであることを特徴とする、請求項16に記載の膜組成物。
- 前記膜組成物中の多価アルコール成分の割合が、1質量%~50質量%であることを特徴とする、請求項16または17に記載の膜組成物。
- 架橋性タンパク質のミクロ粒子を互いに架橋することにより皮膚表面上に膜を形成するための2剤式皮膚外用剤であって、架橋性タンパク質のミクロ粒子を含有する第1剤、及びトランスグルタミナーゼを含有する第2剤、を含んで成る2剤式皮膚外用剤。
- 前記第1剤に含有される架橋性タンパク質のミクロ粒子がエマルション粒子であることを特徴とする、請求項19に記載の2剤式皮膚外用剤。
- 前記第1剤に含有される架橋性タンパク質のエマルション粒子が油中水型エマルション粒子であることを特徴とする、請求項20に記載の2剤式皮膚外用剤。
- 前記第1剤中のミクロ粒子がアニオン性ポリマー成分をさらに含んで成ることを特徴とする、請求項19~21のいずれか一項に記載の2剤式皮膚外用剤。
- 前記アニオン性ポリマーがポリグルタミン酸であることを特徴とする、請求項22に記載の2剤式皮膚外用剤。
- 前記第1剤中のミクロ粒子が多価アルコール成分をさらに含んで成ることを特徴とする、請求項19~23のいずれか一項に記載の2剤式皮膚外用剤。
- 前記多価アルコール成分がグリセリンであることを特徴とする、請求項24に記載の2剤式皮膚外用剤。
- 皮膚表面の凹凸を補正するための化粧方法であって、架橋性タンパク質のミクロ粒子を含有する第1剤及びトランスグルタミナーゼを含有する第2剤の混合物を皮膚表面上の所望の部位に適用するか、あるいは該第1剤及び第2剤を別々に皮膚表面上の所望の部位に適用することにより混合し、そして該部位上で第1剤及び第2剤の混合物を乾燥させることにより、皮膚表面上に該架橋性タンパク質のミクロ粒子が互いに架橋した膜を形成させることを含んで成る、化粧方法。
- 前記第1剤に含有される架橋性タンパク質のミクロ粒子がエマルション粒子であることを特徴とする、請求項16に記載の化粧方法。
- 前記第1剤に含有される架橋性タンパク質のエマルション粒子が油中水型エマルション粒子であることを特徴とする、請求項17に記載の化粧方法。
- 前記第1剤中のミクロ粒子がアニオン性ポリマー成分をさらに含んで成ることを特徴とする、請求項26~28のいずれか一項に記載の化粧方法。
- 前記アニオン性ポリマーがポリグルタミン酸であることを特徴とする、請求項29に記載の化粧方法。
- 前記第1剤中のミクロ粒子が多価アルコール成分をさらに含んで成ることを特徴とする、請求項26~30のいずれか一項に記載の化粧方法。
- 前記多価アルコール成分がグリセリンであることを特徴とする、請求項31に記載の化粧方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801016004A CN101917962B (zh) | 2008-01-15 | 2009-01-14 | 微粒膜组合物 |
JP2009550021A JP5562042B2 (ja) | 2008-01-15 | 2009-01-14 | ミクロ粒子膜組成物 |
US12/735,410 US8697136B2 (en) | 2008-01-15 | 2009-01-14 | Transglutaminase crosslinked protein microparticle film composition |
EP09702338.6A EP2229934A4 (en) | 2008-01-15 | 2009-01-14 | MICRO PARTICLE FILM COMPOSITION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008006117 | 2008-01-15 | ||
JP2008-006117 | 2008-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009090962A1 true WO2009090962A1 (ja) | 2009-07-23 |
Family
ID=40885351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/050393 WO2009090962A1 (ja) | 2008-01-15 | 2009-01-14 | ミクロ粒子膜組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8697136B2 (ja) |
EP (1) | EP2229934A4 (ja) |
JP (1) | JP5562042B2 (ja) |
CN (1) | CN101917962B (ja) |
WO (1) | WO2009090962A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013223644A (ja) * | 2012-04-23 | 2013-10-31 | Dainippon Printing Co Ltd | ヒドロゲル薄膜及び乾燥ゲル薄膜の製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2846748A4 (en) * | 2012-05-08 | 2015-11-04 | Jie Zhang | COMBINED SHEET AND LIQUID SYSTEMS FOR PERCUTANEOUS DELIVERY OF LIDOCAINE, DICLOFENAC, AND OTHER MEDICINES |
CN103421199A (zh) * | 2013-05-09 | 2013-12-04 | 河南工业大学 | 一种利用酶法获得的γ-聚谷氨酸水凝胶及其制备方法 |
US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
CN115350328A (zh) * | 2022-08-19 | 2022-11-18 | 江苏西宏生物医药有限公司 | 一种长效微粒iii型胶原蛋白植入剂 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61152247A (ja) * | 1984-12-26 | 1986-07-10 | Ajinomoto Co Inc | 蛋白質膜の製造法 |
JPS61172807A (ja) * | 1985-01-25 | 1986-08-04 | Ajinomoto Co Inc | 化粧料 |
JPS6274360A (ja) * | 1985-09-28 | 1987-04-06 | 味の素株式会社 | 人工皮膚 |
JPH02169511A (ja) * | 1988-12-21 | 1990-06-29 | Kanebo Ltd | 皮膚化粧料 |
JPH07215894A (ja) * | 1994-01-31 | 1995-08-15 | Ajinomoto Co Inc | 創傷治療剤 |
JPH08506830A (ja) * | 1993-02-19 | 1996-07-23 | グリーン,ハワード | 角質細胞(corneocyte)タンパク質を含有する組成物 |
JPH11349442A (ja) | 1998-06-01 | 1999-12-21 | Pola Chem Ind Inc | シワ・毛穴隠し化粧料 |
JP2000016919A (ja) | 1998-04-30 | 2000-01-18 | Shiseido Co Ltd | 外用組成物 |
JP2006348012A (ja) * | 2005-06-17 | 2006-12-28 | Estate Chemical Kk | 化粧料 |
JP2007224012A (ja) * | 2006-01-30 | 2007-09-06 | Fujifilm Corp | 酵素架橋したタンパク質ナノ粒子 |
JP2008189784A (ja) * | 2007-02-02 | 2008-08-21 | Kyushu Univ | 刺激応答性タンパク質ナノ粒子 |
JP2008285432A (ja) * | 2007-05-16 | 2008-11-27 | Fujifilm Corp | 皮膚外用剤 |
JP2008297241A (ja) * | 2007-05-31 | 2008-12-11 | Fujifilm Corp | ニキビ用皮膚外用剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2071867A1 (en) * | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
AU9313298A (en) | 1997-09-04 | 1999-03-22 | Point Biomedical Corporation | Injectable tissue reconstruction material |
-
2009
- 2009-01-14 US US12/735,410 patent/US8697136B2/en not_active Expired - Fee Related
- 2009-01-14 JP JP2009550021A patent/JP5562042B2/ja not_active Expired - Fee Related
- 2009-01-14 CN CN2009801016004A patent/CN101917962B/zh not_active Expired - Fee Related
- 2009-01-14 EP EP09702338.6A patent/EP2229934A4/en not_active Withdrawn
- 2009-01-14 WO PCT/JP2009/050393 patent/WO2009090962A1/ja active Application Filing
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61152247A (ja) * | 1984-12-26 | 1986-07-10 | Ajinomoto Co Inc | 蛋白質膜の製造法 |
JPS61172807A (ja) * | 1985-01-25 | 1986-08-04 | Ajinomoto Co Inc | 化粧料 |
JPS6274360A (ja) * | 1985-09-28 | 1987-04-06 | 味の素株式会社 | 人工皮膚 |
JPH02169511A (ja) * | 1988-12-21 | 1990-06-29 | Kanebo Ltd | 皮膚化粧料 |
JPH08506830A (ja) * | 1993-02-19 | 1996-07-23 | グリーン,ハワード | 角質細胞(corneocyte)タンパク質を含有する組成物 |
JPH07215894A (ja) * | 1994-01-31 | 1995-08-15 | Ajinomoto Co Inc | 創傷治療剤 |
JP2000016919A (ja) | 1998-04-30 | 2000-01-18 | Shiseido Co Ltd | 外用組成物 |
JPH11349442A (ja) | 1998-06-01 | 1999-12-21 | Pola Chem Ind Inc | シワ・毛穴隠し化粧料 |
JP2006348012A (ja) * | 2005-06-17 | 2006-12-28 | Estate Chemical Kk | 化粧料 |
JP2007224012A (ja) * | 2006-01-30 | 2007-09-06 | Fujifilm Corp | 酵素架橋したタンパク質ナノ粒子 |
JP2008189784A (ja) * | 2007-02-02 | 2008-08-21 | Kyushu Univ | 刺激応答性タンパク質ナノ粒子 |
JP2008285432A (ja) * | 2007-05-16 | 2008-11-27 | Fujifilm Corp | 皮膚外用剤 |
JP2008297241A (ja) * | 2007-05-31 | 2008-12-11 | Fujifilm Corp | ニキビ用皮膚外用剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2229934A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013223644A (ja) * | 2012-04-23 | 2013-10-31 | Dainippon Printing Co Ltd | ヒドロゲル薄膜及び乾燥ゲル薄膜の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20110044928A1 (en) | 2011-02-24 |
CN101917962A (zh) | 2010-12-15 |
EP2229934A4 (en) | 2013-07-10 |
US8697136B2 (en) | 2014-04-15 |
JPWO2009090962A1 (ja) | 2011-05-26 |
CN101917962B (zh) | 2013-09-25 |
EP2229934A1 (en) | 2010-09-22 |
JP5562042B2 (ja) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5904949B2 (ja) | 脂質ペプチド型ゲル化剤と高分子化合物とを含有するゲルシート | |
EP2827837B1 (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails | |
JP5562042B2 (ja) | ミクロ粒子膜組成物 | |
Budai-Szűcs et al. | The effect of the antioxidant on the properties of thiolated poly (aspartic acid) polymers in aqueous ocular formulations | |
WO2015002091A1 (ja) | 水溶性ヒアルロン酸ゲル及びその製造方法 | |
JPWO2014054702A1 (ja) | ヒドロゲル形成材料、プレミックス及びヒドロゲル形成方法 | |
WO2020004649A1 (ja) | 被膜形成組成物 | |
KR101905518B1 (ko) | 세포외기질-실록산 중합체를 함유하는 화장료 조성물 및 그 제조 방법 | |
Picchio et al. | pH-responsive casein-based films and their application as functional coatings in solid dosage formulations | |
JP2008285461A (ja) | 生体用粘着ゲルシートおよびそれを含むシート状化粧料 | |
KR20170099656A (ko) | 보습용 화장료 조성물 | |
Montanari et al. | Halting hyaluronidase activity with hyaluronan-based nanohydrogels: Development of versatile injectable formulations | |
WO2021132045A1 (en) | Anhydrous composition for topical delivery of active ingredients | |
WO2011024942A1 (ja) | マトリックスメタロプロテアーゼ-2(mmp-2)阻害剤 | |
JP6126702B2 (ja) | 多剤耐性グラム陽性菌抗菌剤及び外用剤 | |
Craig et al. | Bacterial protease triggered release of biocides from microspheres with an oily core | |
JP3834563B2 (ja) | アルブチンを利用した安定なナノ乳化粒子の製造方法及びナノ乳化粒子を含有する化粧料組成物 | |
KR20210118879A (ko) | 피부 또는 점막의 외용제 및 그 제조 방법, 및 피부 또는 점막의 외용제의 기제 | |
IT201800008192A1 (it) | Microsfere di acido ialuronico reticolato con urea e contenenti almeno un agente attivo o farmaco | |
KR101193606B1 (ko) | pH 감응성 나노입자 및 생체 유사 계면활성제를 함유하는 피부투과율이 개선된 화장료 조성물 | |
Basto | Optimization of topical delivery for niacinamide using hydrogels and transethosomes for anti-ageing effect | |
Söpper | Development of mucoadhesive carrier systems for flavoring agents and cannabidiol | |
Lionzo et al. | Chitosan as stabilizer and carrier of natural based nanostructures | |
WO2020137220A1 (ja) | 高内油相水中油型乳化組成物 | |
WO2023139492A1 (en) | New system for the topical pharmacological release of an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980101600.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09702338 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009550021 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009702338 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12735410 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |